Oncotarget

Research Papers:

Identification of lipid-phosphatidylserine (PS) as the target of unbiasedly selected cancer specific peptide-peptoid hybrid PPS1

Tanvi J. Desai, Jason E. Toombs, John D. Minna, Rolf A. Brekken and Damith Gomika Udugamasooriya _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:30678-30690. https://doi.org/10.18632/oncotarget.8929

Metrics: PDF 1672 views  |   HTML 4387 views  |   ?  


Abstract

Tanvi J. Desai1, Jason E. Toombs3, John D. Minna3,4,5,6, Rolf A. Brekken3,4,5,7, Damith Gomika Udugamasooriya1,2

1Department of Pharmacological and Pharmaceutical Sciences, University of Houston, Houston, TX 77204, USA

2Department of Cancer Systems Imaging, MD Anderson Cancer Center, Houston, TX 77030, USA

3Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA

4Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA

5Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA

6Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA

7Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA

Correspondence to:

Damith Gomika Udugamasooriya, e-mail: [email protected]

Keywords: phosphatidylserine, peptoids, non-protein biomarkers, anti-cancer agents, lung cancer

Received: December 01, 2015     Accepted: March 31, 2016     Published: April 22, 2016

ABSTRACT

Phosphatidylserine (PS) is an anionic phospholipid maintained on the inner-leaflet of the cell membrane and is externalized in malignant cells. We previously launched a careful unbiased selection targeting biomolecules (e.g. protein, lipid or carbohydrate) distinct to cancer cells by exploiting HCC4017 lung cancer and HBEC30KT normal epithelial cells derived from the same patient, identifying HCC4017 specific peptide-peptoid hybrid PPS1. In this current study, we identified PS as the target of PPS1. We validated direct PPS1 binding to PS using ELISA-like assays, lipid dot blot and liposome based binding assays. In addition, PPS1 recognized other negatively charged and cancer specific lipids such as phosphatidic acid, phosphatidylinositol and phosphatidylglycerol. PPS1 did not bind to neutral lipids such as phosphatidylethanolamine found in cancer and phosphatidylcholine and sphingomyelin found in normal cells. Further we found that the dimeric version of PPS1 (PPS1D1) displayed strong cytotoxicity towards lung cancer cell lines that externalize PS, but not normal cells. PPS1D1 showed potent single agent anti-tumor activity and enhanced the efficacy of docetaxel in mice bearing H460 lung cancer xenografts. Since PS and anionic phospholipid externalization is common across many cancer types, PPS1 may be an alternative to overcome limitations of protein targeted agents.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8929